IQPC 2013 Predictive Toxicology
Summit - London, United Kingdom
Capitalise on the innovative developments in predictive toxicology: Implement the latest in-vitro and in-silico models and address the continual challenge of in-vitro to in-vivo extrapolation The average cost of discovering and developing a drug now costs $900 million. Avoiding late stage drug attrition is critical for keeping costs down. One of the key tools in pharmaceutical R&D is predictive toxicology. Accurately predicting the toxicological effect and efficacy of a drug can improve the drug or identify the cause of the issue preventing any additional costs when these challenges are uncovered in clinical trials. But the questions remain, How do we cost-effectively develop and implement these in-vitro methods as accurately and as early in the drug discovery process as possible? Key to making these strategic decisions is understanding the newest most innovative models, assays and technologies available. For this very purpose Pharma-IQ presents the 5th Annual Predictive Toxicology Summit 2012 to explore the cutting edge techniques, technologies and strategies to enable you to confidently predict drug toxicity.
(Courtesy of http://www.predictivetoxicology.com/Venue.aspx)
IQPC 2013 Predictive Toxicology
Tuesday, February 19, 2013 to Wednesday, February 20, 2013
Millennium Gloucester Hotel, 4-18 Harrington Gardens, London,
SW7 4LH, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.